JP2003508074A - 最も一般的な形態の常染色体性優性遺伝性痙性対麻痺に応答し得るｓｐｇ遺伝子のクローニング、発現および同定 - Google Patents
最も一般的な形態の常染色体性優性遺伝性痙性対麻痺に応答し得るｓｐｇ遺伝子のクローニング、発現および同定Info
- Publication number
- JP2003508074A JP2003508074A JP2001521734A JP2001521734A JP2003508074A JP 2003508074 A JP2003508074 A JP 2003508074A JP 2001521734 A JP2001521734 A JP 2001521734A JP 2001521734 A JP2001521734 A JP 2001521734A JP 2003508074 A JP2003508074 A JP 2003508074A
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- nucleic acid
- seq
- polypeptide
- spg4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000008675 hereditary spastic paraplegia Diseases 0.000 title claims abstract description 49
- 238000010367 cloning Methods 0.000 title claims abstract description 13
- 230000014509 gene expression Effects 0.000 title claims description 31
- 101150111241 spg gene Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 claims abstract description 104
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 93
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 89
- 229920001184 polypeptide Polymers 0.000 claims abstract description 87
- 230000035772 mutation Effects 0.000 claims abstract description 74
- 239000002299 complementary DNA Substances 0.000 claims abstract description 61
- 108090001068 Spastin Proteins 0.000 claims abstract description 32
- 239000013598 vector Substances 0.000 claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 239000000126 substance Substances 0.000 claims abstract description 7
- 238000009007 Diagnostic Kit Methods 0.000 claims abstract description 4
- 102000004880 Spastin Human genes 0.000 claims abstract 2
- 150000007523 nucleic acids Chemical group 0.000 claims description 110
- 102100038829 Spastin Human genes 0.000 claims description 87
- 108090000623 proteins and genes Proteins 0.000 claims description 82
- 101000664527 Homo sapiens Spastin Proteins 0.000 claims description 69
- 102000039446 nucleic acids Human genes 0.000 claims description 53
- 108020004707 nucleic acids Proteins 0.000 claims description 53
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 52
- 101150055520 SPG4 gene Proteins 0.000 claims description 38
- 239000000523 sample Substances 0.000 claims description 35
- 239000012634 fragment Substances 0.000 claims description 33
- 239000002773 nucleotide Substances 0.000 claims description 30
- 125000003729 nucleotide group Chemical group 0.000 claims description 30
- 108020004414 DNA Proteins 0.000 claims description 29
- 230000003321 amplification Effects 0.000 claims description 27
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 27
- 241000282414 Homo sapiens Species 0.000 claims description 24
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 14
- 241000124008 Mammalia Species 0.000 claims description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 239000012472 biological sample Substances 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 230000000295 complement effect Effects 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 10
- 238000012216 screening Methods 0.000 claims description 10
- 238000004458 analytical method Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000004075 alteration Effects 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 4
- 238000003205 genotyping method Methods 0.000 claims description 4
- 230000001900 immune effect Effects 0.000 claims description 4
- 230000001594 aberrant effect Effects 0.000 claims description 3
- 108700028369 Alleles Proteins 0.000 claims description 2
- 239000012620 biological material Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 239000013599 cloning vector Substances 0.000 claims 1
- 238000011002 quantification Methods 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 10
- 230000009261 transgenic effect Effects 0.000 abstract description 8
- 238000012512 characterization method Methods 0.000 abstract description 4
- 238000002405 diagnostic procedure Methods 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 41
- 102000004169 proteins and genes Human genes 0.000 description 41
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 30
- 238000003752 polymerase chain reaction Methods 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 239000000047 product Substances 0.000 description 20
- 241001529936 Murinae Species 0.000 description 15
- 108700024394 Exon Proteins 0.000 description 14
- 238000009396 hybridization Methods 0.000 description 14
- 238000012163 sequencing technique Methods 0.000 description 14
- 238000012217 deletion Methods 0.000 description 13
- 230000037430 deletion Effects 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 11
- 108091033319 polynucleotide Proteins 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 9
- 108020004635 Complementary DNA Proteins 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 108700026244 Open Reading Frames Proteins 0.000 description 6
- 101150078320 SPAST gene Proteins 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 108010058643 Fungal Proteins Proteins 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 102000056978 human SPAST Human genes 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000010627 oxidative phosphorylation Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 108091006112 ATPases Proteins 0.000 description 4
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 108091060211 Expressed sequence tag Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000008238 Muscle Spasticity Diseases 0.000 description 4
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 4
- 108020005067 RNA Splice Sites Proteins 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 4
- 210000002459 blastocyst Anatomy 0.000 description 4
- 238000004590 computer program Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000001964 muscle biopsy Methods 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 208000018198 spasticity Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 102000009067 AAA Proteins Human genes 0.000 description 3
- 108010087671 AAA Proteins Proteins 0.000 description 3
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102000005741 Metalloproteases Human genes 0.000 description 3
- 108010006035 Metalloproteases Proteins 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 101100521046 Xenopus laevis psmc3-a gene Proteins 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 230000014621 translational initiation Effects 0.000 description 3
- 238000010396 two-hybrid screening Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102100021765 E3 ubiquitin-protein ligase RNF139 Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101001106970 Homo sapiens E3 ubiquitin-protein ligase RNF139 Proteins 0.000 description 2
- 101000803685 Homo sapiens Vacuolar protein sorting-associated protein 4A Proteins 0.000 description 2
- 101000803689 Homo sapiens Vacuolar protein sorting-associated protein 4B Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 101100149979 Mus musculus Spast gene Proteins 0.000 description 2
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 description 2
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 2
- 108091092724 Noncoding DNA Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 101100162195 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) AFG3 gene Proteins 0.000 description 2
- 101100267551 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YME1 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 102100035085 Vacuolar protein sorting-associated protein 4A Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000000688 human artificial chromosome Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000037436 splice-site mutation Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- HLXHCNWEVQNNKA-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1h-inden-2-amine Chemical compound COC1=CC=C2CC(N)CC2=C1 HLXHCNWEVQNNKA-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241001132374 Asta Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 101710110830 Beta-agarase Proteins 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 102100032566 Carbonic anhydrase-related protein 10 Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241001302160 Escherichia coli str. K-12 substr. DH10B Species 0.000 description 1
- 101150029299 G4 gene Proteins 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 description 1
- 101000867836 Homo sapiens Carbonic anhydrase-related protein 10 Proteins 0.000 description 1
- 101001048716 Homo sapiens ETS domain-containing protein Elk-4 Proteins 0.000 description 1
- 101001092930 Homo sapiens Prosaposin Proteins 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000016202 Proteolipids Human genes 0.000 description 1
- 108010010974 Proteolipids Proteins 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 101100263884 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) VPS4 gene Proteins 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102100022483 Sodium channel and clathrin linker 1 Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 1
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000005082 bioluminescent agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 208000025613 complex hereditary spastic paraplegia Diseases 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940041984 dextran 1 Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000891 luminescent agent Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 230000007117 mitochondrial recruitment Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000000276 neural tube Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000010397 one-hybrid screening Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000005080 phosphorescent agent Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000009609 prenatal screening Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003751 purification from natural source Methods 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR99/11097 | 1999-09-03 | ||
| FR9911097A FR2798138B1 (fr) | 1999-09-03 | 1999-09-03 | Clonage, expression et caracterisation du gene spg4 responsable de la forme la plus frequente de paraplegie spastique autosomique dominante |
| PCT/FR2000/002433 WO2001018198A1 (fr) | 1999-09-03 | 2000-09-04 | Clonage, expression et caracterisation du gene spg4 responsable de la forme la plus frequente de paraplegie spastique autosomique dominante |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011158305A Division JP5965594B2 (ja) | 1999-09-03 | 2011-07-19 | 最も一般的な形態の常染色体性優性遺伝性痙性対麻痺に応答し得るｓｐｇ遺伝子のクローニング、発現および同定 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003508074A true JP2003508074A (ja) | 2003-03-04 |
| JP2003508074A5 JP2003508074A5 (enExample) | 2008-02-21 |
Family
ID=9549552
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001521734A Withdrawn JP2003508074A (ja) | 1999-09-03 | 2000-09-04 | 最も一般的な形態の常染色体性優性遺伝性痙性対麻痺に応答し得るｓｐｇ遺伝子のクローニング、発現および同定 |
| JP2011158305A Expired - Lifetime JP5965594B2 (ja) | 1999-09-03 | 2011-07-19 | 最も一般的な形態の常染色体性優性遺伝性痙性対麻痺に応答し得るｓｐｇ遺伝子のクローニング、発現および同定 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011158305A Expired - Lifetime JP5965594B2 (ja) | 1999-09-03 | 2011-07-19 | 最も一般的な形態の常染色体性優性遺伝性痙性対麻痺に応答し得るｓｐｇ遺伝子のクローニング、発現および同定 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US6924126B1 (enExample) |
| JP (2) | JP2003508074A (enExample) |
| CA (2) | CA2848454C (enExample) |
| FR (1) | FR2798138B1 (enExample) |
| WO (1) | WO2001018198A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5312314B2 (ja) * | 2006-03-30 | 2013-10-09 | デューク ユニヴァーシティー | 家族性痙性対麻痺の根底にある新規遺伝子の同定 |
| EP1897891A1 (en) * | 2006-09-11 | 2008-03-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Diagnosis of hereditary spastic paraplegias (HSP) by detection of a mutation in the KIAA1840 gene or protein |
| WO2009127211A1 (en) * | 2008-04-14 | 2009-10-22 | Aarhus Universitet | Methods and kits for determining spinal dysmyelination |
| JP6208104B2 (ja) * | 2014-09-16 | 2017-10-04 | 株式会社日立製作所 | 生体認証システム、生体認証処理装置、生体認証方法、生体情報取得端末および情報端末 |
| KR101889072B1 (ko) | 2017-09-15 | 2018-08-16 | 한국생명공학연구원 | 디지털 PCR을 이용한 유전성 강직성 대마비(Hereditary spastic paraplegia, HSP) 관련 유전자 SPG4의 거대결손 검증법 |
| CN117820470B (zh) * | 2024-03-04 | 2024-05-31 | 暨南大学 | 人源性重组抗Spastin抗体及其制备方法和应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998046743A1 (en) * | 1997-04-15 | 1998-10-22 | The Wellcome Trust Limited As Trustee To The Wellcome Trust | Novel ldl-receptor |
| WO1999037662A1 (en) * | 1998-01-27 | 1999-07-29 | Millennium Pharmaceuticals, Inc. | Spoil protein and nucleic acid molecules and uses therefor |
| WO1999042622A1 (en) * | 1998-02-23 | 1999-08-26 | Dana-Farber Cancer Institute, Inc. | Method for identifying mismatch repair glycosylase reactive sites, compound and uses thereof_____________________________________ |
-
1999
- 1999-09-03 FR FR9911097A patent/FR2798138B1/fr not_active Expired - Lifetime
-
2000
- 2000-09-04 CA CA2848454A patent/CA2848454C/fr not_active Expired - Lifetime
- 2000-09-04 CA CA2348657A patent/CA2348657C/fr not_active Expired - Lifetime
- 2000-09-04 US US09/830,902 patent/US6924126B1/en not_active Expired - Lifetime
- 2000-09-04 JP JP2001521734A patent/JP2003508074A/ja not_active Withdrawn
- 2000-09-04 WO PCT/FR2000/002433 patent/WO2001018198A1/fr not_active Ceased
-
2005
- 2005-06-20 US US11/155,492 patent/US20050266479A1/en not_active Abandoned
-
2011
- 2011-07-19 JP JP2011158305A patent/JP5965594B2/ja not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998046743A1 (en) * | 1997-04-15 | 1998-10-22 | The Wellcome Trust Limited As Trustee To The Wellcome Trust | Novel ldl-receptor |
| WO1999037662A1 (en) * | 1998-01-27 | 1999-07-29 | Millennium Pharmaceuticals, Inc. | Spoil protein and nucleic acid molecules and uses therefor |
| WO1999042622A1 (en) * | 1998-02-23 | 1999-08-26 | Dana-Farber Cancer Institute, Inc. | Method for identifying mismatch repair glycosylase reactive sites, compound and uses thereof_____________________________________ |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5965594B2 (ja) | 2016-08-10 |
| CA2848454C (fr) | 2018-04-17 |
| CA2348657A1 (fr) | 2001-03-15 |
| US6924126B1 (en) | 2005-08-02 |
| CA2348657C (fr) | 2014-07-08 |
| FR2798138A1 (fr) | 2001-03-09 |
| US20050266479A1 (en) | 2005-12-01 |
| JP2011254824A (ja) | 2011-12-22 |
| CA2848454A1 (fr) | 2001-03-15 |
| FR2798138B1 (fr) | 2004-05-21 |
| WO2001018198A1 (fr) | 2001-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080057506A1 (en) | Polycystic xidney disease PKD2 gene and uses thereop | |
| US20130035260A1 (en) | Genes involved in inflammatory bowel diseases and use thereof | |
| JP5965594B2 (ja) | 最も一般的な形態の常染色体性優性遺伝性痙性対麻痺に応答し得るｓｐｇ遺伝子のクローニング、発現および同定 | |
| JP2001521041A (ja) | 良性の家族性新生児痙攣（ｂｆｎｃ）および他の癲癇において突然変異されたｋｃｎｑ２およびｋｃｎｑ３−カリウムチャンネル遺伝子 | |
| JP2003530814A (ja) | 不整脈に関連するヒトｍｉｎｋ遺伝子突然変異 | |
| WO1997042314A1 (en) | Nucleic acid encoding spinocerebellar ataxia-2 and products related thereto | |
| US20070224624A1 (en) | Nucleic acid encoding spinocerebellar ataxia-2 and products related thereto | |
| WO2004018633A2 (en) | Abca13 nucleic acids and proteins, and uses thereof | |
| AU4386299A (en) | A nucleic acid encoding a retinoblastoma binding protein (RBP-7) and polymorphic markers associated with said nucleic acid | |
| Kashuba et al. | Initial isolation and analysis of the human Kv1. 7 (KCNA7) gene, a member of the voltage-gated potassium channel gene family | |
| JP2002521045A (ja) | Ｋｖｌｑｔ１−ｑｔ延長症候群 | |
| US20020102551A1 (en) | Nope polypeptides, encoding nucleic acids and methods of use | |
| US7151161B1 (en) | Human genes of chromosome 11q13.3 | |
| US7166713B2 (en) | Variant cleavage stimulation factor and its encoding nucleic acid | |
| AU2004202848B2 (en) | A nucleic acid encoding a retinoblastoma binding protein (RBP-7) and polymorphic markers associated with said nucleic acid | |
| AU740606B2 (en) | Men1, the gene associated with multiple endocrine neoplasia type 1, menin polypeptides, and uses thereof | |
| WO2001029266A2 (en) | Identification of arsacs mutations and methods of use therefor | |
| JP2002504559A (ja) | ベスト黄斑ジストロフィー遺伝子 | |
| US20030180887A1 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
| CA2357987A1 (en) | Genetic sequence related to bone diseases | |
| CA2462143A1 (en) | Genetic sequence related to bone diseases | |
| WO2002020719A2 (en) | MAMMALIAN NON-ERYTHROID Rh TYPE C GENES AND GLYCOPROTEINS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070904 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070904 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071227 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100820 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101122 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101130 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101220 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101228 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110120 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110127 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110221 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110318 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110719 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20111104 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20111129 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20120113 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20130508 |